Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells $537,250.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 25,000 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $21.49, for a total value of $537,250.00. Following the completion of the sale, the director directly owned 772,652 shares of the company’s stock, valued at $16,604,291.48. The trade was a 3.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Josef Parvizi also recently made the following trade(s):

• On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $20.26, for a total value of $506,500.00.

CeriBell Trading Down 0.7%

NASDAQ CBLL opened at $21.20 on Friday. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $28.23. The business has a 50 day moving average price of $15.25 and a 200-day moving average price of $14.69. The company has a market cap of $786.52 million, a price-to-earnings ratio of -14.04 and a beta of 1.35.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.06. The business had revenue of $22.59 million during the quarter, compared to the consensus estimate of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. As a group, equities analysts expect that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CBLL has been the topic of several recent research reports. TD Cowen dropped their price target on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Canaccord Genuity Group raised their target price on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday. BTIG Research reissued a “buy” rating and set a $30.00 target price on shares of CeriBell in a research report on Monday. Raymond James Financial started coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 target price on the stock. Finally, JPMorgan Chase & Co. cut their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, CeriBell currently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

Institutional Trading of CeriBell

Hedge funds and other institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell in the 3rd quarter worth approximately $33,000. Tower Research Capital LLC TRC raised its position in shares of CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after buying an additional 1,256 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its stake in CeriBell by 161.0% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after buying an additional 3,502 shares during the period. Finally, Sherbrooke Park Advisers LLC purchased a new position in CeriBell during the third quarter worth about $135,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.